Protara Therapeutics, Inc. (NASDAQ:TARA – Get Free Report) major shareholder Opaleye Management Inc. sold 46,574 shares of the business’s stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $2.26, for a total transaction of $105,257.24. Following the completion of the sale, the insider now owns 90,000 shares in the company, valued at approximately $203,400. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Opaleye Management Inc. also recently made the following trade(s):
- On Tuesday, June 25th, Opaleye Management Inc. sold 12,725 shares of Protara Therapeutics stock. The shares were sold at an average price of $2.26, for a total transaction of $28,758.50.
- On Thursday, May 30th, Opaleye Management Inc. sold 9,230 shares of Protara Therapeutics stock. The stock was sold at an average price of $2.94, for a total transaction of $27,136.20.
- On Tuesday, May 21st, Opaleye Management Inc. sold 33,000 shares of Protara Therapeutics stock. The shares were sold at an average price of $3.06, for a total transaction of $100,980.00.
- On Friday, May 17th, Opaleye Management Inc. sold 70,885 shares of Protara Therapeutics stock. The shares were sold at an average price of $3.25, for a total value of $230,376.25.
- On Thursday, May 9th, Opaleye Management Inc. sold 30,600 shares of Protara Therapeutics stock. The shares were sold at an average price of $3.09, for a total value of $94,554.00.
Protara Therapeutics Stock Performance
Shares of TARA opened at $2.08 on Monday. The firm has a market capitalization of $42.83 million, a price-to-earnings ratio of -0.56 and a beta of 1.85. Protara Therapeutics, Inc. has a 52 week low of $1.04 and a 52 week high of $5.24. The business’s fifty day moving average price is $2.79 and its two-hundred day moving average price is $2.96.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Protara Therapeutics stock. Oppenheimer & Co. Inc. purchased a new position in shares of Protara Therapeutics, Inc. (NASDAQ:TARA – Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 10,000 shares of the company’s stock, valued at approximately $40,000. Oppenheimer & Co. Inc. owned about 0.09% of Protara Therapeutics at the end of the most recent reporting period. Institutional investors own 38.13% of the company’s stock.
Analyst Upgrades and Downgrades
Several research analysts recently issued reports on TARA shares. Oppenheimer upped their price target on shares of Protara Therapeutics from $26.00 to $30.00 and gave the stock an “outperform” rating in a research report on Monday, April 22nd. HC Wainwright reiterated a “buy” rating and set a $23.00 target price on shares of Protara Therapeutics in a research report on Monday, May 6th.
Get Our Latest Stock Analysis on Protara Therapeutics
About Protara Therapeutics
Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Read More
- Five stocks we like better than Protara Therapeutics
- Comparing and Trading High PE Ratio Stocks
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- What is the NASDAQ Stock Exchange?
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for Protara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.